Radiolabeled prostate-specific membrane antigen (PSMA) inhibitors 18 Improved synthesis of [F]DCFPyL
The improved synthesis method for preparing radiolabeled [18F]DCFPyL solves the problem of the lack of efficient molecular imaging methods in the diagnosis and treatment of prostate cancer. It realizes the preparation of high-purity and high specific activity [18F]DCFPyL, which is suitable for high-sensitivity molecular imaging of prostate cancer.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- JOHNS HOPKINS UNIVERSITY
- Filing Date
- 2017-06-09
- Publication Date
- 2026-06-12
AI Technical Summary
In current prostate cancer diagnosis and treatment, there is a lack of efficient molecular imaging techniques, especially for radioactive tracers used for prostate-specific membrane antigen (PSMA), which are difficult to meet the requirements for high sensitivity and high specificity.
A modified synthetic method was used to prepare a radiolabeled prostate-specific membrane antigen inhibitor [18F]DCFPyL. The DCFPyL precursor was radiofluorinated, including ester moiety protection, deprotection and purification steps, and the synthesis was carried out using an automated radiochemical synthesizer to ensure high purity and high efficiency of radiolabeling.
[18F]DCFPyL with high purity and high specific activity is provided for high-sensitivity molecular imaging of prostate cancer, improving the accuracy and efficiency of diagnosis and treatment.
Smart Images
Figure CN122187724A_ABST